ABSTRACT. To investigate the chemerin level in the ChineseHan population with metabolic syndrome and its relationship with each metabolic syndrome component [body mass index (BMI), blood pressure, blood lipids, and blood glucose], we selected 30 patients with metabolic syndrome and 30 healthy control subjects. The chemerin level was measured by enzyme immunoassay in these 2 groups. The subjects' weight, blood pressure, BMI, waist circumference, fasting blood glucose, fasting insulin, lipids, and glycated hemoglobin were simultaneously detected. The t-test, correlation analysis, and multiple regression analysis were used to perform statistical analysis. We found that plasma chemerin level was higher in the metabolic syndrome group than that in the control group (97.61 ± 6.49 vs 70.26 ± 6.97, t = 15.73, P < 0.05). The plasma chemerin level was positively correlated with systolic blood pressure, waist circumference, BMI, waist-to-hip ratio, fasting blood glucose, fasting insulin, and glycated hemoglobin (r = 0.548, 0.442, 0.359, 0.556, 0.613, 0.581, and 0.572, respectively; all P < 0.05). However, it was negatively correlated with high-density lipoprotein cholesterol (r = -0.378, P < 0.05). Therefore, we concluded that plasma chemerin level was correlated with obesity, blood pressure, and high-density lipoprotein cholesterol, suggesting that it may play a role in the

ABSTRACT. The aim of this study was to detect the serum adipose triglyceride lipase (ATGL) levels in obesity and newly diagnosed type 2 diabetes patients, and to explore the association between ATGL with glucose and lipid metabolism. We enrolled 66 patients with type 2 diabetes and 48 patients with normal glucose regulation, who were divided into an overweight or obese subgroup and a normal weight subgroup according to body mass index (BMI) ≥ 25 kg/m 2 . The enzyme-linked immunosorbent assay was used to detect fasting blood glucose, blood lipids, fasting insulin, and ATGL levels. The serum ATGL level in the overweight or obese group was lower than that in the non-obese group including patients with type 2 diabetes and normal glucose regulation: 239 ± 61 vs 355 ± 54 mg/L and 242 ± 60 vs 383 ± 58 mg/L, respectively (t = 22.53, t = 8.23, P < 0.05). The Pearson correlation analysis showed that fasting serum ATGL was negatively correlated with body fat content, BMI, waist-to-hip ratio, Association of serum ATGL with obesity and diabetes triglycerides, and the homeostatic model assessment-insulin resistance level (r = -0.271, r = -0.238, r = -0.375, r = -0.313, and r = -0.164, respectively, P < 0.05). The stepwise regression analysis showed that the waist-to-hip ratio and body fat content were independently associated with the serum ATGL level. Our results indicated that the ATGL level may be closely related to obesity.